Changing Shapes: From Proteins to Business Models

Cypralis was spun out from parent company Selcia to exploit its extensive expertise and know-how in targeting a large family of protein targets involved in many acute and chronic diseases. We hear from Dr Hans Fliri, Chairman of Selcia and Cypralis and Simon Kerr, CEO at Cypralis, about the company and the importance of peptidyl-prolyl isomerases, known as PPIases.

Download the pdf to read the full article

Download